Torben Frøstrup Hansen

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Colonic Neoplasms 75%
3. MicroRNAs 69%
4. Circulating Tumor DNA 42%
5. Neoplasms 40%
6. Rectal Neoplasms 34%
7. Drug Therapy 34%
8. Bevacizumab 32%
9. Oxaliplatin 32%
10. Biomarkers 26%
11. Survival 23%
12. Capecitabine 23%
13. Progression-Free Survival 20%
14. Single Nucleotide Polymorphism 19%
15. Vascular Endothelial Growth Factor A 19%
16. Therapeutics 18%
17. Biliary Tract Neoplasms 17%
18. Epidermal Growth Factor 16%
19. Natural Killer Cells 15%
20. Circulating MicroRNA 14%
21. Prostatic Neoplasms 14%
22. Microvessels 14%
23. DNA 13%
24. Genes 13%
25. Lung Neoplasms 13%
26. Panitumumab 12%
27. Recurrence 11%
28. Confidence Intervals 11%
29. Vascular Endothelial Growth Factor Receptor-2 10%
30. Tumor-Infiltrating Lymphocytes 10%
31. Angiogenesis Inhibitors 9%
32. Population 9%
33. Microsatellite Instability 9%
34. XELOX 9%
35. Methylation 9%
36. Immunotherapy 9%
37. Combination Drug Therapy 9%
38. Bronchoalveolar Lavage 8%
39. Chemoradiotherapy 8%
40. Denmark 8%
41. Mutation 8%
42. Polymerase Chain Reaction 8%
43. Neuropeptide Y 7%
44. Homeobox Genes 7%
45. Disease-Free Survival 7%
46. DNA Mismatch Repair 7%
47. Adenocarcinoma 6%
48. Response Evaluation Criteria in Solid Tumors 6%
49. Exons 6%
50. gemcitabine 6%